LONDON AND HONG KONG, Nov 10, 2022 – (ACN Newswire) – Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter ended September 30, 2022.Third Quarter 2022 and Recent Highlights:– Reported third quarter 2022 revenue of US$80 million — Reported loss from operations of US$9 million…
Read More
